Sunshine Biopharma (SBFM) Assets Average (2011 - 2026)

Sunshine Biopharma's Assets Average history runs 14 years deep, the most recent figure standing at $29.0 million for Q1 2026.

• Quarterly Assets Average fell 2.91% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.0 million (down 2.91% YoY) and the FY2025 annual result came in at $30.3 million, up 4.72% from the prior year.
• Assets Average was $29.0 million for Q1 2026 at Sunshine Biopharma, down from $30.8 million in the prior quarter.
• Across five years, Assets Average topped out at $41.4 million in Q3 2022 and bottomed at $7.8 million in Q1 2022.
• A 5-year average of $29.1 million and a median of $29.7 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average surged 1818.4% — and 2023, when it plunged 32.34%.
• Sunshine Biopharma's Assets Average stood at $35.1 million in 2022, then retreated by 21.55% to $27.5 million in 2023, then rose by 10.22% to $30.3 million in 2024, then advanced by 1.57% to $30.8 million in 2025, then decreased by 5.78% to $29.0 million in 2026.
• Business Quant data shows SBFM's Assets Average at $29.0 million in Q1 2026, $30.8 million in Q4 2025, and $31.7 million in Q3 2025.